MK 7680

Drug Profile

MK 7680

Alternative Names: MK-7680

Latest Information Update: 21 Aug 2015

Price : $50

At a glance

  • Originator Merck Sharp & Dohme
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 01 Apr 2015 Merck Sharp & Dohme completes a phase I trial in Hepatitis C in Belgium (NCT02269059)
  • 01 Dec 2014 Phase-I clinical trials in Hepatitis C in Belgium (PO) (NCT02269059)
  • 28 Oct 2014 Merck Sharp & Dohme plans a phase I trial in Hepatitis C in Belgium (NCT02269059)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top